UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

ZIOPHARM Oncology, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share (Title of Class of Securities)

> 98973P101 (CUSIP Number)

December 31, 2011 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

⊠ Rule 13d-1(c)

□ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8

CUSIP No. 98973P101

0051	P NO. 985	,, ,,	101		
1.	Names	of R	eporting Persons.		
	QVT Financial LP				
	I.R.S. Identification Nos. of above persons (entities only).				
	11-369				
2.	 Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) ⊠ 				
3.	SEC Us	e Or	lly		
4.	Citizona	hin	or Place of Organization		
4.	4. Citizenship or Place of Organization				
	Dela	elaware			
		5.	Sole Voting Power		
Number of			0		
Shares		6.	Shared Voting Power		
Beneficially Owned by			2,351,476		
Each Reporting		7.	Sole Dispositive Power		
Person			0		
With:		8.	Shared Dispositive Power		
			2,351,476		
9.	Aggregate Amount Beneficially Owned by Each Reporting Person				
	2,35	51,4	76		
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)				
11.	11. Percent of Class Represented by Amount in Row (9)		Class Represented by Amount in Row (9)		
	2.94%				
12.	Type of	Rep	orting Person (See Instructions)		
	PN				

Page 2 of 8

CUSIP No. 98973P101

C031	P No. 989	// JI	101
1.	Names of Reporting Persons.		
	QVT Financial GP LLC		
	I.R.S. Identification Nos. of above persons (entities only).		
	11-369		
2.	 Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) ⊠ 		
3.	SEC Us	e Or	ıly
4.	4. Citizenship or Place of Organization		
	Dela	awa	re
		5.	Sole Voting Power
Number of			0
Shares		6.	Shared Voting Power
Beneficially Owned by			2,351,476
Each Reporting		7.	Sole Dispositive Power
Person			0
With:		8.	Shared Dispositive Power
			2,351,476
9.	Aggregate Amount Beneficially Owned by Each Reporting Person		
	2,351,476		
10.	. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)		
11.	1. Percent of Class Represented by Amount in Row (9)		
	2.94%		
12.	Type of	Rep	orting Person (See Instructions)
	00		
		-	

Page 3 of 8

CUSIP No. 98973P101

CUSI	USIP No. 98973P101			
1.	Names of Reporting Persons.			
	QVT Fund LP			
	I.R.S. Identification Nos. of above persons (entities only).			
	98-041			
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) ⊠			
3.	SEC Us	e Or	ıly	
4.	Citizens	hip	or Place of Organization	
	Cay	mai	n Islands	
		5.	Sole Voting Power	
Number of			0	
Shares		6.	Shared Voting Power	
Beneficially Owned by			2,131,546	
Each Reporting		7.	Sole Dispositive Power	
Person			0	
With:		8.	Shared Dispositive Power	
			2,131,546	
9.	Aggregate Amount Beneficially Owned by Each Reporting Person			
	2,131,546			
10.	0. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)			
11.	1. Percent of Class Represented by Amount in Row (9)			
	2.67%			
12.	Type of	Rep	orting Person (See Instructions)	
	PN			

Page 4 of 8

CUSIP No. 98973P101

0001	2031 100. 303737 101				
1.	. Names of Reporting Persons.				
	QVT Associates GP LLC				
	I.R.S. Identification Nos. of above persons (entities only).				
	01-079				
 Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) ⊠ 		ppropriate Box if a Member of a Group (See Instructions) b) ⊠			
3.	SEC Us	e Or	lly		
4.	Citizens	hip	or Place of Organization		
	Dela	awa	re		
		5.	Sole Voting Power		
Number of Shares			0		
		6.	Shared Voting Power		
Beneficially Owned by			2,351,476		
Each Reporting		7.	Sole Dispositive Power		
Person			0		
With:		8.	Shared Dispositive Power		
			2,351,476		
9.	Aggregate Amount Beneficially Owned by Each Reporting Person				
	2,351,476				
10.					
11.	11. Percent of Class Represented by Amount in Row (9)		lass Represented by Amount in Row (9)		
	2.94%				
12.	Type of	Rep	orting Person (See Instructions)		
	00				
L	· · ·				

Page 5 of 8

Item 1	(a).	Name of Issuer
		ZIOPHARM Oncology, Inc. (the "Issuer")
Item 1	(b).	Address of Issuer's Principal Executive Offices
		The address of the Issuer's principal executive offices is:
		1180 Avenue of the Americas, 19th Floor, New York, New York 10036, United States
Item 2	(a).	Name of Person Filing
Item 2	(b).	Address of Principal Business Office or, if none, Residence
Item 2	(c).	Citizenship
		QVT Financial LP 1177 Avenue of the Americas, 9th Floor New York, New York 10036 Delaware Limited Partnership
		QVT Financial GP LLC 1177 Avenue of the Americas, 9th Floor New York, New York 10036 Delaware Limited Liability Company
		QVT Fund LP Walkers SPV, Walker House 87 Mary Street George Town, Grand Cayman, KY1 9001 Cayman Islands Cayman Islands Limited Partnership
		QVT Associates GP LLC 1177 Avenue of the Americas, 9th Floor New York, New York 10036 Delaware Limited Liability Company
Item 2	(d).	Title of Class of Securities
		Common stock, \$0.001 par value per share (the "Common Stock").
Item 2	(e).	CUSIP Number
		The CUSIP number of the Common Stock is 98973P101.
Item 3.	If this s	tatement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
	(a)	□ Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).
	(b)	\square Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	□ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	□ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
	(f)	□ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
	(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
	(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	□ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
	(k)	Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b) (1)(ii)(J), please specify the type of institution:

Page 6 of 8

Item 4. Ownership.

(a) Amount beneficially owned as of December 31, 2011:

QVT Financial LP ("QVT Financial") is the investment manager for QVT Fund LP (the "Fund") and Quintessence Fund L.P. ("Quintessence"). The Fund beneficially owns 2,131,546 shares of Common Stock. Quintessence beneficially owns 219,930 shares of Common Stock. Accordingly, QVT Financial may be deemed to be the beneficial owner of an aggregate amount of 2,351,476 shares of Common Stock, consisting of the shares of Common Stock owned by the Fund and Quintessence.

QVT Financial GP LLC, as General Partner of QVT Financial, may be deemed to beneficially own the same number of shares of Common Stock reported by QVT Financial. QVT Associates GP LLC, as General Partner of the Fund and Quintessence, may be deemed to beneficially own the aggregate number of shares of Common Stock owned by the Fund and Quintessence, and accordingly, QVT Associates GP LLC may be deemed to beneficially own 2,351,476 shares of Common Stock.

The percentage disclosed in Item 11 of the Cover Pages for each reporting person is calculated based upon the sum of (i) 78,101,324 shares of Common Stock outstanding, which is the total number of shares issued and outstanding as reported in the Issuer's Prospectus Supplement filed with the Securities and Exchange Commission on January 23, 2012 and (ii) Rule 13d-3(d) (1)(i).

(b) Percent of class:

See Item 11 of the Cover Pages to this Schedule 13G.

- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote

0

(ii) Shared power to vote or to direct the vote

See item (a) above.

(iii) Sole power to dispose or to direct the disposition of

0

(iv) Shared power to dispose or to direct the disposition of

See item (a) above.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following... \boxtimes .

As of December 31, 2011, each of the reporting persons ceased to be the beneficial owner of more than five percent of the class of securities.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of Group

Not Applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 7 of 8

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2012

QVT FINANCIAL LP

By QVT Financial GP LLC, its General Partner

By: /s/ Tracy Fu Name: Tracy Fu

Title: Managing Member

By:/s/ Meg EisnerName:Meg EisnerTitle:Authorized Signatory

QVT FINANCIAL GP LLC

By:	/s/ Tracy Fu	By:	/s
Name:	Tracy Fu	Name:	Т
Title:	Managing Member	Title:	Ν
By:	/s/ Meg Eisner	By:	/s
Name:	Meg Eisner	Name:	Ν
Title:	Authorized Signatory	Title:	A
		Page 8 of 8	

QVT FUND LP

By QVT Associates GP LLC, its General Partner

By:/s/ Tracy FuName:Tracy FuTitle:Managing MemberBy:/s/ Meg EisnerName:Meg EisnerTitle:Authorized SignatoryQVT ASSOCIATES GP LLCBy:/s/ Tracy FuName:Tracy FuTitle:Managing MemberBy:/s/ Meg EisnerName:Tracy FuTitle:Managing MemberBy:/s/ Meg EisnerName:Meg Eisner

Title: Authorized Signatory

Page 8 of 8